Answers are grounded in this paper and cite their sources.
Retrospective study evaluates KL-6 as a biomarker for lung disease severity and therapy response in ASMD type B, suggesting it indicates patient condition improvements.
Acid sphingomyelinase deficiency (ASMD) type B is frequently complicated by interstitial lung disease without validated circulating pulmonary biomarkers. In this retrospective longitudinal study of five patients treated with enzyme replacement therapy, plasma KL-6 was evaluated in relation to CT-based severity, DLCO, and treatment response. Higher pre-treatment KL-6 concentrations were observed with higher exploratory CT severity grades, and KL-6 levels generally decreased or remained stable during follow-up. A transient rise occurred during SARS-CoV-2 infection. KL-6 may reflect dynamic alveolar epithelial injury in ASMD.
No takes yet. Share an insight, caveat, or question.
Cifuentes-Uribe et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: